Special Combination of BBI608 and Pembrolizumab

NCT ID: NCT02851004

Last Updated: 2021-09-05

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 55 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-10-31
• Study Completion Date: 2021-08-23

Brief Summary

the efficacy and safety of BBI608 in combination with pembrolizumab

Detailed Description

This is a multicenter, open-label Phase Ib/II study to exploratively evaluate the efficacy and safety of BBI608 in combination with pembrolizumab in patients with metastatic colorectal cancer (CRC) not responded to or intolerant of standard chemotherapy.The same analysis will be performed for the additional cohort to the Phase II part, consisting of patients with metastatic CMS 1 or 4, MMS, CRC not responsive to or intolerant of standard chemotherapy.

Conditions

Metastatic Colorectal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BBI608 + Pembrolizumab

BBI608 and Pembrolizumab

Group Type: EXPERIMENTAL

Napabucasin

Intervention Type: DRUG

1 cycle is 21days.

BBI608: Oral administration at a dose of 240mg or 480 mg twice daily (BID), every day.

[Additional cohort to the Phase II part] Oral administration at a dose of 240mg mg BID, every day

The therapy will be repeated until meeting the discontinuation criteria.

Pembrolizumab

Intervention Type: DRUG

1 cycle is 21days.

Pembrolizumab: Administration at a dose of 200 mg/body on Day 1 of each cycle

[Additional cohort to the Phase II part] Administration at a dose of 200 mg/body on Day 1 of each cycle.

The therapy will be repeated until meeting the discontinuation criteria.

Interventions

Napabucasin

1 cycle is 21days.

BBI608: Oral administration at a dose of 240mg or 480 mg twice daily (BID), every day.

[Additional cohort to the Phase II part] Oral administration at a dose of 240mg mg BID, every day

The therapy will be repeated until meeting the discontinuation criteria.

Intervention Type: DRUG

Pembrolizumab

1 cycle is 21days.

Pembrolizumab: Administration at a dose of 200 mg/body on Day 1 of each cycle

[Additional cohort to the Phase II part] Administration at a dose of 200 mg/body on Day 1 of each cycle.

The therapy will be repeated until meeting the discontinuation criteria.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients who personally provided written consent to be the subjects of the study

2. Age of 20 years or older on the day of informed consent

3. [Phase Ib] Histologically confirmed gastrointestinal cancer

[Phase II] Histologically confirmed colon or rectal cancer that is adenocarcinoma , and identification of at least the KRAS codon 12 and 13 mutation status determined by RAS gene testing. Confirmation of the microsatellite instability (MSI) status.

[Additional cohort to the Phase II part] Histologically confirmed colon or rectal cancer that is adenocarcinoma, and identification of RAS mutation status. Identification of CMS 1 or 4 and MSS by screening tests.

4. [Phase Ib] Gastrointestinal cancer not responded to or intolerant of standard chemotherapy

[Phase II]A history of treatment with one or more regimens of the following standard chemotherapies for metastatic CRC, and being not responded to or tolerated the chemotherapies

[Additional cohort to the Phase II part] In accordance with Cohort B in the Phase II part.

5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1

6. Patients with evaluable lesions (Cohort A in Phase II and Phase Ib) or measurable lesions (Cohort B in Phase II and the additional cohort to the Phase II part) specified in the RECIST version 1.1

7. Patients with adequate organ function based on the following laboratory values measured within 7 days before enrollment

8. Women of childbearing potential who are negative in a pregnancy test within 7 days before enrollment. Both male and female patients who consent to practice appropriate contraception during the study and for 4 months after the discontinuation of the protocol treatment

9. Patients with an expected survival of at least 3 months

Exclusion Criteria

1. Patients who received chemotherapy, molecular-targeted agents and/or palliative radiotherapy within 2 weeks before the start of the protocol treatment or have not recovered from toxicity caused by previous treatment

2. Patients who underwent general anesthesia, surgery requiring hospitalization and extensive radiotherapy within 4 weeks before the start of the protocol treatment or minor surgery such as implantation of a central venous access device within two weeks before the start of the protocol treatment

3. Patients with active central nervous system metastases or carcinomatous meningitis.

4. Pregnant or lactating women

5. Patients who are unable or not willing to take BBI608 capsules every day

6. Patients with gastrointestinal disease markedly interfering with the absorption of oral formulations as judged by the investigator

7. Patients with active autoimmune disease requiring systemic treatment within 2 years before the start of the protocol treatment.

8. Patients with a history or signs of interstitial lung disease or active non-infectious pneumonitis

9. Patients who underwent organ or bone marrow transplantation

10. Patients who received a live vaccine within 30 days before the start of the protocol treatment

11. Patients who participated in another clinical study within 4 weeks before the start of the protocol treatment and used or using an investigational drug or device

12. Patients who previously received immunotherapy with drugs targeting PD-1, PD-L1 and/or PD-L2 or BBI608 therapy, or took part in a clinical study of pembrolizumab or BBI608

13. Patients with uncontrollable complications

14. Patients with a history of other malignancies within 3 years before the start of the protocol treatment.

15. Patients with clinically significant Electrocardiogram (ECG) abnormalities

16. Patients with a history of Human Immunodeficiency Virus (HIV)

17. Patients with active hepatitis B or C

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sumitomo Pharma Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Takayuki Yoshino

OTHER

Sponsor Role: lead

Responsible Party

Takayuki Yoshino

Director of Gastrointestinal Oncology Division

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Takayuki Yoshino, Dr

Role: STUDY_CHAIR

National Cancer Center Hospital East

Locations

National Cancer Center Hospital East

Kashiwa, Chiba, Japan

Countries

Japan

Other Identifiers

EPOC1503

Identifier Type: -

Identifier Source: org_study_id